|
Cayman Islands
(州或其他管辖范围
成立公司或组织) |
| |
2834
(主要标准工业
分类代码号) |
| |
Not Applicable
(I.R.S. Employer
识别码) |
|
|
Portia Ku, Esq.
Vincent Lin, Esq. O’Melveny & Myers LLP Times Square Tower 7 Times Square New York, NY 10036 +1-212-326-2000 |
| |
Yu-Hsin Lin
Belite Bio, Inc 5820 Oberlin Drive, Suite 101, San Diego, CA 92121 +1-858-246-6240 |
| |
Richard Anslow, Esq.
John J. Hart, Esq. Ellenoff Grossman&Schole LLP 1345 Avenue of the Americas, 11th Floor New York, New York 10105 +1-212-370-1300 |
|
|
Prospectus Summary
|
| | | | 1 | | |
|
Risk Factors
|
| | | | 17 | | |
|
有关前瞻性陈述的特别说明
|
| | | | 86 | | |
|
Use of Proceeds
|
| | | | 88 | | |
|
Dividend Policy
|
| | | | 89 | | |
|
Capitalization
|
| | | | 90 | | |
|
Dilution
|
| | | | 92 | | |
|
民事责任的可执行性
|
| | | | 94 | | |
|
公司历史和结构
|
| | | | 96 | | |
|
选定的合并财务数据
|
| | | | 97 | | |
|
管理层对财务状况和经营成果的讨论和分析
|
| | | | 98 | | |
|
Business
|
| | | | 112 | | |
|
Regulations
|
| | | | 138 | | |
|
Management
|
| | | | 167 | | |
|
主要股东
|
| | | | 176 | | |
|
关联方交易
|
| | | | 178 | | |
|
股本说明
|
| | | | 183 | | |
|
美国存托股份说明
|
| | | | 195 | | |
|
有资格未来出售的股票
|
| | | | 205 | | |
|
Taxation
|
| | | | 207 | | |
|
Underwriting
|
| | | | 212 | | |
|
与此产品相关的费用
|
| | | | 223 | | |
|
Legal Matters
|
| | | | 224 | | |
|
Experts
|
| | | | 225 | | |
|
在哪里可以找到更多信息
|
| | | | 226 | | |
|
合并财务报表索引
|
| | | | F-1 | | |
Indication
|
| |
Clinical Trials
|
| |
Trial Participants
|
| |
Estimated Timeline
|
|
STGD1 | | | 第一阶段单次和多次递增剂量试验 | | | Healthy adult subjects | | | Completed | |
| | | Phase 1b trial | | | 患有STGD1的青少年患者 | | | Completed | |
| | | Phase 2 trial | | | 患有STGD1的青少年患者 | | | 正在进行,预计将在12、15、18和21个月捕获临时数据读出,并在24个月捕获最终数据读出。 | |
| | | Phase 3 trial | | | 患有STGD1的青少年患者 | | | Initiated | |
Dry AMD | | | 第一阶段单次递增剂量试验 | | | Healthy adult subjects | | | Completed | |
| | | Phase 2 or Phase 3 trial | | |
Patients with dry AMD
|
| | 2022 | |
| | |
For the Years Ended
December 31, |
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
| | |
(amounts in $ and in thousands,
除股票和每股数据外) |
| |||||||||
Expenses | | | | | | | | | | | | | |
Research and development
|
| | | | 3,688 | | | | | | 7,419 | | |
一般和行政
|
| | | | 2,055 | | | | | | 2,378 | | |
Total operating expenses
|
| | | | 5,743 | | | | | | 9,797 | | |
Loss from operations
|
| | | | (5,743) | | | | | | (9,797) | | |
Other income (expense): | | | | | | | | | | | | | |
Interest income
|
| | | | 12 | | | | | | 5 | | |
Interest expense
|
| | | | (21) | | | | | | — | | |
Other income
|
| | | | — | | | | | | 126 | | |
Total other (expense) income, net
|
| | | | (9) | | | | | | 131 | | |
Loss before income tax
|
| | | | (5,752) | | | | | | (9,666) | | |
Income tax expense
|
| | | | (1) | | | | | | — | | |
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | |
其他综合收益(亏损) | | | | | | | | | | | | | |
外币折算调整,扣除零税
|
| | | | 6 | | | | | | (152) | | |
Total comprehensive loss
|
| | | $ | (5,747) | | | | | $ | (9,818) | | |
计算中使用的普通股加权平均数: | | | | | | | | | | | | | |
—Basic and Diluted
|
| | | | 8,790,397 | | | | | | 9,569,932 | | |
每股普通股净亏损 | | | | | | | | | | | | | |
—Basic and Diluted
|
| | | $ | (0.65) | | | | | $ | (1.01) | | |
| | |
As of
December 31, 2020 |
| |
As of
December 31, 2021 |
| ||||||
| | |
(amounts in $ and in
thousands) |
| |||||||||
选定的合并资产负债表数据: | | | | | | | | | | | | | |
Cash
|
| | | $ | 25,618 | | | | | $ | 17,344 | | |
Total assets
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
Total liabilities
|
| | | $ | 972 | | | | | $ | 1,635 | | |
可转换优先股合计
|
| | | $ | 31,806 | | | | | $ | 31,806 | | |
Total shareholders’ deficit
|
| | | $ | (7,037) | | | | | $ | (15,093) | | |
总负债、可转换优先股和股东亏损
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
| | |
As of December 31, 2021
|
| |||||||||||||||
| | |
Actual
|
| |
Pro forma
|
| |
Pro forma
as adjusted(1) |
| |||||||||
| | |
(除
外,以千美元为单位
用于股票和每股数据) |
| |||||||||||||||
| | | | $ | | | | | $ | | | | | $ | | | |||
可转换优先股: | | | | | | | | | | | | | | | | | | | |
A系列可转换优先股,面值0.0001美元;2,377,642股(实际),无授权股份(预计和预计调整后);2,377,642股已发行和已发行股票(实际);无已发行和已发行股份(预计和预计调整后)
|
| | | $ | 8,806 | | | | | | — | | | | | | — | | |
B系列可转换优先股,面值0.0001美元;5,443,272股(实际),无授权股份(预计和预计调整后);5,443,272股已发行和已发行股票(实际);无已发行和已发行股份(预计和预计调整后)
|
| | | $ | 23,000 | | | | | | — | | | | | | — | | |
可转换优先股合计
|
| | | $ | 31,806 | | | | | | — | | | | | | — | | |
Shareholders’ deficit: | | | | | | | | | | | | | | | | | | | |
普通股,每股面值0.0001美元;492,179,086股授权股份;10,274,403股已发行和已发行股份(实际);18,095,317股和24,095,317股已发行和已发行股份(预计和预计调整后)
|
| | | | 1 | | | | | | 2 | | | | | | 2 | | |
新增实收资本
|
| | | | 12,325 | | | | | | 44,130 | | | | | | 75,561 | | |
累计其他综合损失
|
| | | | (196) | | | | | | (196) | | | | | | (196) | | |
Accumulated deficit
|
| | | | (27,223) | | | | | | (27,223) | | | | | | (27,223) | | |
股东权益合计(亏损)
|
| | | | (15,093) | | | | | | 16,713 | | | | | | 48,144 | | |
| | |
Per
Ordinary Share |
| |
Per
ADS |
|
假设首次公开募股价格
|
| |
US$6.00
|
| | US$6.00 | |
截至2021年12月31日的有形账面净值
|
| |
US$1.55
|
| | US$1.55 | |
优先股转换生效后的预计有形账面净值
|
| |
US$0.88
|
| | US$0.88 | |
我们的优先股转换和本次发售生效后的调整后有形账面净值的预计值
|
| |
US$2.00
|
| | US$2.00 | |
本次发行中向新投资者摊薄的有形账面净值金额
|
| |
US$4.00
|
| | US$4.00 | |
| | |
Ordinary Shares
Purchased |
| |
Total Consideration
|
| |
Average
Price Per Ordinary Share |
| |
Average
Price Per ADS |
| |||||||||||||||
| | |
Number
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| |||||||||||||||
现有股东
|
| | | | 18,095,317 | | | | | | 75% | | | | US$44,132,000 | | | | | 55% | | | | US$2.44 | | | US$2.44 | |
New investors
|
| | | | 6,000,000 | | | | | | 25% | | | | US$36,000,000 | | | | | 45% | | | | US$6.00 | | | US$6.00 | |
Total
|
| | | | 24,095,317 | | | | | | 100.0% | | | | US$80,132,000 | | | | | 100.0% | | | | | | | | |
| | |
For the Year Ended December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
| | |
(单位:千美元,
除外
每股和每股金额) |
| |||||||||
精选合并经营报表和全面亏损 | | | | | | | | | | | | | |
总运营费用(1)
|
| | | | 5,743 | | | | | | 9,797 | | |
其他(费用)收入总额,净额
|
| | | | (9) | | | | | | 131 | | |
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | |
全面亏损
|
| | | $ | (5,747) | | | | | $ | (9,818) | | |
计算基本普通股和稀释普通股时使用的普通股加权平均数
|
| | | | 8,790,397 | | | | | | 9,569,932 | | |
每股普通股基本和摊薄净亏损
|
| | | | (0.65) | | | | | | (1.01) | | |
| | |
Year Ended
|
| |||||||||
| | |
December 31,
2020 |
| |
December 31,
2021 |
| ||||||
| | |
(amounts in $
and in thousands) |
| |||||||||
研发
|
| | | $ | 77 | | | | | $ | 52 | | |
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | |
Total
|
| | | $ | 1,363 | | | | | $ | 1,530 | | |
| | |
As of
December 31, 2020 |
| |
As of
December 31, 2021 |
| ||||||
| | |
(amounts in $
and in thousands) |
| |||||||||
选定的合并资产负债表数据: | | | | | | | | | | | | | |
Cash
|
| | | $ | 25,618 | | | | | $ | 17,344 | | |
Total assets
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
Total liabilities
|
| | | $ | 972 | | | | | $ | 1,635 | | |
可转换优先股合计
|
| | | $ | 31,806 | | | | | $ | 31,806 | | |
股东亏损总额
|
| | | $ | (7,037) | | | | | $ | (15,093) | | |
总负债、可转换优先股和股东亏损
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
| | |
For the Years Ended December 31,
|
| |
Change
|
| | ||||||||||||||||||||
| | |
2020
|
| |
2021
|
| | ||||||||||||||||||||
| | |
(amounts in $ and in thousands)
|
| | | | | | | |
(%)
|
| | ||||||||||||||
Expenses | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
研发(1)
|
| | | | 3,688 | | | | | | 7,419 | | | | | | 3,731 | | | | | | 101.2 | | | | ||
一般和行政(1)
|
| | | | 2,055 | | | | | | 2,378 | | | | | | 323 | | | | | | 15.7 | | | | ||
总运营费用
|
| | | | 5,743 | | | | | | 9,797 | | | | | | 4,054 | | | | | | 70.6 | | | | ||
Loss from operations
|
| | | | (5,743) | | | | | | (9,797) | | | | | | (4,054) | | | | | | 70.6 | | | | ||
Other income (expense): | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Interest income
|
| | | | 12 | | | | | | 5 | | | | | | (7) | | | | | | (58.3) | | | | ||
Interest expense
|
| | | | (21) | | | | | | — | | | | | | 21 | | | | | | 100 | | | | ||
Other income
|
| | | | — | | | | | | 126 | | | | | | 126 | | | | | | | | | | ||
其他(费用)收入总额,净额
|
| | | | (9) | | | | | | 131 | | | | | | 140 | | | | | | 1,555.6 | | | | ||
Loss before income tax
|
| | | | (5,752) | | | | | | (9,666) | | | | | | (3,914) | | | | | | 168.0 | | | | ||
Income tax expense
|
| | | | (1) | | | | | | — | | | | | | 1 | | | | | | 100 | | | | ||
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | | | | | (3,915) | | | | | | 168.0 | | | | ||
其他综合收益(亏损) | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
外币折算调整,扣除零税
|
| | | | 6 | | | | | | (152) | | | | | | (158) | | | | | | (2,633.3) | | | | ||
全面亏损
|
| | | $ | (5,747) | | | | | $ | (9,818) | | | | | $ | (4,071) | | | | | $ | (70.8) | | | |
| | |
Years ended December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
研发
|
| | | $ | 77 | | | | | $ | 52 | | |
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | |
Total
|
| | | $ | 1,363 | | | | | $ | 1,530 | | |
| | |
For the Years Ended December 31,
|
| |||||||||||||||||||||
(千美元,百分比除外)
|
| |
2020
|
| |
2021
|
| ||||||||||||||||||
| | |
$
|
| |
%
|
| |
$
|
| |
%
|
| ||||||||||||
签约研究费用和临床试验费用
|
| | | | 1,979 | | | | | | 53.7 | | | | | | 6,384 | | | | | | 86.0 | | |
咨询费和专业服务费
|
| | | | 319 | | | | | | 8.6 | | | | | | 492 | | | | | | 6.6 | | |
Royalties
|
| | | | 1,187 | | | | | | 32.2 | | | | | | 103 | | | | | | 1.4 | | |
Other expenses
|
| | | | 203 | | | | | | 5.5 | | | | | | 440 | | | | | | 6.0 | | |
Total
|
| | | $ | 3,688 | | | | | | 100 | | | | | $ | 7,419 | | | | | | 100 | | |
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Grant Date Fair Value |
| |
Weighted
Average Remaining Term (Years) |
| |
Aggregate
Intrinsic Value |
| |||||||||||||||
Outstanding as of January 1, 2020
|
| | | | 1,335,794 | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | 9.96 | | | | | | 3,301 | | |
Granted
|
| | | | 2,807,381 | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (727,676) | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (19,601) | | | | | $ | 0.1191 | | | | | $ | 2.4733 | | | | | | — | | | | | | — | | |
Outstanding as of December 31, 2020
|
| | | | 3,395,898 | | | | | $ | 0.3832 | | | | | $ | 2.2946 | | | | | | 9.80 | | | | | | 7,834 | | |
Granted
|
| | | | 41,736 | | | | | $ | 4.2254 | | | | | $ | 0.4626 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (706,406) | | | | | $ | 0.3289 | | | | | $ | 2.3311 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (748,667) | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Outstanding Options, December 31, 2021
|
| | | | 1,982,561 | | | | | $ | 0.4626 | | | | | $ | 2.2571 | | | | | | 8.82 | | | | | $ | 4,480 | | |
截至2021年12月31日,已授予并预计将授予期权
|
| | | | 844,774 | | | | | $ | 0.3935 | | | | | $ | 2.3052 | | | | | | 8.58 | | | | | $ | 1,969 | | |
截至2021年12月31日的可行使期权
|
| | | | 356,067 | | | | | $ | 0.2291 | | | | | $ | 2.4192 | | | | | | 7.99 | | | | | $ | 891 | | |
| | |
As of
December 17, 2019 |
| |
As of
December 23, 2020 |
| |
As of
March 1, 2021 |
| |||||||||
Risk-free interest rate
|
| |
1.72% – 1.74%
|
| | | | 0.51% | | | | | | 0.87% | | | |||
预期波动范围
|
| |
35.50% – 35.72%
|
| | | | 36.59% | | | | | | 36.75% | | | |||
Exercise multiple
|
| | | | 2.8 | | | | | | 2.8 | | | | | | 2.8 | | |
预期股息收益率
|
| | | | — | | | | | | — | | | | | | — | | |
| | |
Years ended December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
研发
|
| | | $ | 77 | | | | | $ | 52 | | |
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | |
Total
|
| | | $ | 1,363 | | | | | $ | 1,530 | | |
Indication
|
| |
Clinical Trials
|
| |
Trial Participants
|
| |
Estimated Timeline
|
|
STGD1
|
| |
第一阶段单次和多次递增剂量试验
|
| |
Healthy adult subjects
|
| |
Completed
|
|
| Phase 1b trial | | | 患有STGD1的青少年患者 | | | Completed | | ||
| Phase 2 trial | | | 患有STGD1的青少年患者 | | | 正在进行中,预计在12个月、15个月、18个月和21个月捕获临时数据读出,并在24个月捕获最终数据读出。 | | ||
| Phase 3 trial | | | 患有STGD1的青少年患者 | | | Initiated | | ||
Dry AMD
|
| |
第一阶段单次递增剂量试验
|
| |
Healthy adult subjects
|
| |
Completed
|
|
| Phase 2 or Phase 3 trial | | | Patients with dry AMD | | | 2022 | |
Adverse Events
|
| |
Severity
|
| |
Relationship
to Drug |
| |
Frequency
(#Patients) |
| |
%
Recovered |
| |
% On-going
|
| |||||||||
黄视/色视
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 7/11 | | | |
7/7 (100%)
|
| | | | 0/7 | | |
延迟暗适应(DDA)
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 7/11 | | | |
7/7 (100%)
|
| | | | 0/7 | | |
夜视障碍
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 1/11 | | | |
1/1 (100%)
|
| | | | 0/1 | | |
Adverse Events
|
| |
Severity
|
| |
Relationship
to Drug |
| |
Frequency
(#Patients) |
| |
%
Recovered |
| |
% On-going
|
| ||||||
黄视/色视
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 6/13 | | | |
3/6 (50%)
|
| |
3/6 (50%)
|
|
延迟暗适应(DDA)
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 8/13 | | | |
1/8 (12.5%)
|
| |
7/8 (87.5%)
|
|
夜视障碍
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 1/13 | | | |
0/1
|
| |
1/1 (100%)
|
|
增加FM100上的错误分数
|
| | | | 温和的 | | | |
Probably Related
|
| | | | 1/13 | | | |
0/1
|
| |
1/1 (100%)
|
|
Adverse Events
|
| |
Severity
|
| |
Frequency (#Subjects)
|
|
黄花 - 黄色在色觉上更突出 | | |
Mild
|
| |
1/29
|
|
Adverse Events
|
| |
Severity
|
| |
Frequency (#Subjects)
|
|
延迟暗适应(DDA) | | |
Mild
|
| |
16/24
|
|
Xanthopsia - 黄色在色觉上更突出 | | |
Mild
|
| |
1/24
|
|
畏光 - 对光的敏感度 | | |
Mild
|
| |
1/24
|
|
Ocular migraine | | |
Mild
|
| |
1/24
|
|
间歇性消化不良(消化不良) | | |
Mild
|
| |
1/24
|
|
Migraine | | |
Moderate
|
| |
1/24
|
|
Patent
Family No. |
| |
Type of Patent
|
| |
Issued Countries/ Regions
and/or Application Type |
| |
Pending
Countries/ Regions and/or Application Type |
| |
Termination Date
(mm/dd/yyyy) |
| |
Subject to
“March-in Rights” (Yes/ No) |
|
1 | | | Utility – Methods of Use | | |
U.S
Europe Japan |
| | N.A | | | 11/22/2031 | | | Yes | |
2 | | | Utility – Methods of Use | | | U.S | | | N.A | | | 04/30/2033 | | | Yes | |
3 | | | 公用事业 - 制造和物质组成 | | |
U.S
U.S Divisional #1 Europe Europe Divisional |
| |
U.S Divisional #2
Hong Kong |
| | 03/13/2034 | | | Yes | |
4 | | | 公用事业 - 制造和物质组成 | | |
U.S
U.S Continuation #1 U.S Continuation #2 Europe |
| | N.A | | | 03/13/2034 | | | Yes | |
5 | | | 公用事业 - 制造和物质组成 | | |
U.S
U.S Divisional |
| | N.A | | | 03/13/2034 | | | Yes | |
6 | | | 公用事业 - 制造和物质组成 | | |
U.S
U.S Continuation |
| | N.A | | | 03/13/2034 | | | Yes | |
7 | | |
Utility – Manufacture
和物质的组成 |
| |
U.S
U.S Continuation #1 美国续集#2美国续集#3 U.S Continuation #4 Europe Australia India Mexico Japan Philippines China Singapore Indonesia |
| |
U.S Continuation
#5 Hong Kong South Korea Myanmar Thailand Canada China Divisional New Zealand Brazil Europe Divisional |
| | 04/29/2035 | | | Yes | |
8 | | | Utility – Methods of Use | | | N.A | | |
U.S
Europe Hong Kong China |
| | 08/01/2039 | | | Yes | |
Patent
Family No. |
| |
Type of Patent
|
| |
Issued Countries/
Regions and/or Application Type |
| |
Pending
Countries/ Regions and/or Application Type |
| |
Termination
Date (mm/dd/yyyy) |
| |
Subject to
“March-in Rights” (Yes/ No) |
|
9 | | |
Utility – Methods of
Use |
| |
U.S,
U.S Divisional #1 |
| |
U.S Divisional #2
Europe Taiwan Hong Kong |
| | 06/14/2038 | | | No | |
Patent
Family No. |
| |
Type of Patent
|
| |
Issued Countries/
Regions and/or Application Type |
| |
Pending
Countries/ Regions and/or Application Type |
| |
Expected
Termination Date (mm/dd/yyyy) |
| |
Subject to
“March-in Rights” (Yes/ No) |
|
10 | | |
Utility – Methods of
Use |
| | N.A | | |
Europe
Taiwan Hong Kong |
| | 06/14/2038 | | | No | |
11 | | | Utility – Formulations | | | N.A | | |
U.S
Europe Australia Canada China India Israel Japan South Korea Singapore Taiwan |
| | 07/06/2040 | | | No | |
12 | | | 实用程序 - 辅助诊断 | | | N.A | | | U.S Provisional | | | 05/21/2042 | | | No | |
13 | | | Utility – Formulation | | | N.A | | | U.S Provisional | | | 11/23/2042 | | | No | |
14 | | |
Utility – Assessing
Visual Function |
| | N.A | | | U.S Provisional | | | 04/14/2043 | | | No | |
Functions
|
| |
Number of
Employees |
| |
% of Total
|
| ||||||
Finance and Accounting
|
| | | | 5 | | | | | | 42% | | |
研究与开发
|
| | | | 7 | | | | | | 58% | | |
Total | | | | | 12 | | | | | | 100% | | |
Name
|
| |
Age
|
| |
Positions(s)
|
|
Yu-Hsin Lin | | |
44
|
| | 首席执行官兼董事会主席* | |
Hao-Yuan Chuang | | |
38
|
| | 董事首席财务官* | |
Nathan L. Mata | | |
56
|
| | 首席科学官 | |
Ching-Chen Chiu | | |
52
|
| |
临床运营副总裁
|
|
Wan-Shan Chen | | |
36
|
| | Director* | |
Hung-Wei Chen | | |
40
|
| | Director* | |
John M. Longo | | |
53
|
| | 独立董事提名者# | |
Ita Lu | | |
45
|
| | 独立董事提名者# | |
Gary C. Biddle | | |
70
|
| | 独立董事提名者# | |
Name
|
| |
Ordinary
Shares Underlying Options |
| |
Exercise
Price (US$/Share) |
| |
Date of Grant
|
| |
Date of Expiration
|
| ||||||
Yu-Hsin Lin
|
| | | | 827,814 | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
| | | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Hao-Yuan Chuang
|
| | | | 579,471 | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
| | | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Nathan L. Mata
|
| | | | 748,667 | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Ching-Chen Chiu
|
| | | | 350,000 | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Wan-Shan Chen
|
| | | | * | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
Hung-Wei Chen
|
| | | | * | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
John M. Longo
|
| | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Gary C. Biddle
|
| | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
所有董事和高管
a group |
| | |
|
2,853,442
|
| | | | | | | | | | | | | |
| | |
普通股受益
在本次发行之前拥有 |
| |
实益拥有的普通股
After This Offering |
| ||||||||||||||||||||||||
| | |
Ordinary
Shares |
| |
% of
Beneficial Ownership† |
| |
Ordinary
Shares |
| |
% of
Beneficial Ownership |
| |
% of
aggregate voting power†† |
| |||||||||||||||
董事和高管**: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Yu-Hsin Lin(1)
|
| | | | 2,463,015 | | | | | | 13.61% | | | | | | 2,773,758 | | | | | | 11.51% | | | | | | 11.51% | | |
Hao-Yuan Chuang(2)
|
| | | | 529,193 | | | | | | 2.92% | | | | | | 532,241 | | | | | | 2.21% | | | | | | 2.21% | | |
Nathan L. Mata
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Ching-Chen Chiu
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Wan-Shan Chen(3)
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Hung-Wei Chen(4)
|
| | | | 193,526 | | | | | | 1.07% | | | | | | * | | | | | | * | | | | | | * | | |
约翰·M·隆戈(独立董事提名人)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
伊塔鲁(独立董事提名者)(5)。
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
加里·C·比德尔(独立董事提名人)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
主要股东: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
林氏生物科学国际有限公司(6)。
|
| | | | 13,928,597 | | | | | | 76.97% | | | | | | 16,428,597 | | | | | | 68.18% | | | | | | 68.18% | | |
Securities/Purchaser
|
| |
Date of Issuance
|
| |
Number of Securities
|
| |
Exercise
Price |
| |||
Options | | | | | | | | | | | | | |
某些董事、高级管理人员和员工
|
| |
December 17, 2019
|
| |
购买最多1,335,794股普通股的选择权
|
| | | $ | 0.1191 | | |
某些董事、高级管理人员和员工
|
| |
December 23, 2020
|
| |
购买最多2,807,381股普通股的选择权
|
| | | $ | 0.4386(1) | | |
某些关键顾问
|
| |
March 1, 2021
|
| |
购买最多41,736股普通股的选择权
|
| | | $ | 4.2254 | | |
某些董事、高级管理人员和员工
|
| |
April 18, 2022#
|
| |
购买最多1,698,667股普通股的选择权
|
| | | $ | 6.00(2) | | |
Service
|
| |
Fees
|
|
·任何获发美国存托凭证的人或任何根据股票股息或其他免费股票分配、红利分配、股票拆分或其他分配(转换为现金的除外)就美国存托股份分配而获得分配的人 | | | Up to US$0.05 per ADS issued | |
·取消美国存托凭证,包括终止存款协议的情况 | | | Up to US$0.05 per ADS cancelled | |
·现金股利分配 | | | Up to US$0.05 per ADS held | |
·出售权利、证券和其他权利的现金权利(现金股息除外)和/或现金收益的分配 | | | Up to US$0.05 per ADS held | |
·根据行使权利分配美国存托凭证。 | | | Up to US$0.05 per ADS held | |
·发行美国存托凭证以外的证券或购买额外美国存托凭证的权利 | | | Up to US$0.05 per ADS held | |
• Depositary services | | | 在开户银行建立的适用记录日期持有的美国存托股份最高可达0.05美元 | |
If we:
|
| |
Then:
|
|
更改我们普通股的面值或面值 | | | 托管人收到的现金、股票或其他证券将成为存款证券。 | |
对任何存放的证券进行重新分类、拆分或合并 | | | 每个美国存托股份将自动代表其在新存入的证券中所占的平均份额。 | |
在未分配给您的普通股上分配证券,或
资本重组、重组、合并、清算、出售我们的全部或几乎所有资产,或采取任何类似行动 |
| | 托管人可以将其收到的部分或全部现金、股票或其他证券进行分配。它还可能提供新的美国存托凭证或要求您交出未偿还的美国存托凭证,以换取识别新存入证券的新的美国存托凭证。 | |
Name
|
| |
Number of ADSs
|
| |||
The Benchmark Company,LLC
|
| | | | 6,000,000 | | |
Total
|
| | | | 6,000,000 | | |
| | |
Total
|
| |||||||||||||||
| | |
Per ADS
|
| |
No Exercise
|
| |
Full exercise
|
| |||||||||
Public offering price
|
| | | 美元 | | | | | | 美元 | | | | | 美元 | | | ||
承保折扣和佣金(1)
|
| | | 美元 | | | | | | 美元 | | | | | 美元 | | | ||
未扣除费用的收益给我们
|
| | | 美元 | | | | | | 美元 | | | | | 美元 | | | |
|
SEC Registration Fee
|
| | | 美元 | 4,000 | | |
|
FINRA Filing Fee
|
| | | | 8,000 | | |
|
证券交易所入市和上市费
|
| | | | 75,000 | | |
|
印刷费和雕刻费
|
| | | | 126,000 | | |
|
Legal Fees and Expenses
|
| | | | 1,697,000 | | |
|
会计费和费用
|
| | | | 84,000 | | |
|
Miscellaneous
|
| | | | 155,000 | | |
| Total | | | | 美元 | 2,149,000 | | |
| | |
PAGE(S)
|
| |||
独立注册会计师事务所报告
|
| | | | F-2 | | |
截至2020年12月31日和2021年12月31日的合并资产负债表
|
| | | | F-3 | | |
截至2020年12月31日和2021年12月31日的年度综合经营报表和全面亏损
|
| | | | F-4 | | |
截至2020年12月31日和2021年12月31日的年度可转换优先股和股东亏损合并报表
|
| | | | F-5 | | |
截至2020年12月31日和2021年12月31日的年度合并现金流量表
|
| | | | F-6 | | |
合并财务报表附注
|
| | | | F-7 | | |
| | |
December 31
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
ASSETS | | | | ||||||||||
Current Assets
Cash |
| | | $ | 25,618 | | | | | $ | 17,344 | | |
预付款和其他流动资产
|
| | | | 50 | | | | | | 87 | | |
Total current assets
|
| | | | 25,668 | | | | | | 17,431 | | |
财产和设备,净额
|
| | | | 46 | | | | | | 94 | | |
物业和设备预付款
|
| | | | 20 | | | | | | — | | |
延期发售成本
|
| | | | — | | | | | | 815 | | |
Security deposits
|
| | | | 7 | | | | | | 8 | | |
TOTAL ASSETS
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
负债、可转换优先股和股东亏损
|
| | | ||||||||||
流动负债 | | | | | | | | | | | | | |
应付关联方的其他款项
|
| | | $ | 26 | | | | | $ | 71 | | |
应计费用和其他负债
|
| | | | 946 | | | | | | 1,564 | | |
流动负债总额
|
| | | | 972 | | | | | | 1,635 | | |
TOTAL LIABILITIES
|
| | | | 972 | | | | | | 1,635 | | |
承付款和或有事项 | | | | | | | | | | | | | |
可转换优先股 | | | | | | | | | | | | | |
截至2020年12月31日和2021年12月31日,A系列可转换优先股,面值0.0001美元,授权、已发行和已发行股票2,377,642股
|
| | | | 8,806 | | | | | | 8,806 | | |
截至2020年12月31日和2021年12月31日,B系列可转换优先股,面值0.0001美元,授权、发行和发行的股票5,443,272股
|
| | | | 23,000 | | | | | | 23,000 | | |
可转换优先股合计
|
| | | | 31,806 | | | | | | 31,806 | | |
股东亏损 | | | | | | | | | | | | | |
普通股,每股票面价值0.0001美元;492,179,086股授权股份;
9,567,997 and 10,274,403 shares issued and outstanding as of December 31, 2020 and 2021, respectively |
| | | | 1 | | | | | | 1 | | |
新增实收资本
|
| | | | 10,563 | | | | | | 12,325 | | |
累计其他综合损失
|
| | | | (44) | | | | | | (196) | | |
Accumulated deficit
|
| | | | (17,557) | | | | | | (27,223) | | |
股东亏损总额
|
| | | | (7,037) | | | | | | (15,093) | | |
总负债、可转换优先股和股东亏损
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
| | |
For the Years Ended
December 31, |
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Expenses | | | | | | | | | | | | | |
研发
|
| | | | 3,688 | | | | | | 7,419 | | |
一般和行政
|
| | | | 2,055 | | | | | | 2,378 | | |
总运营费用
|
| | | | 5,743 | | | | | | 9,797 | | |
Loss from operations
|
| | | | (5,743) | | | | | | (9,797) | | |
Other income (expense): | | | | | | | | | | | | | |
Interest income
|
| | | | 12 | | | | | | 5 | | |
Interest expense
|
| | | | (21) | | | | | | — | | |
Other income
|
| | | | — | | | | | | 126 | | |
其他(费用)收入总额,净额
|
| | | | (9) | | | | | | 131 | | |
Loss before income tax
|
| | | | (5,752) | | | | | | (9,666) | | |
Income tax expense
|
| | | | (1) | | | | | | — | | |
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | |
其他综合收益(亏损) | | | | | | | | | | | | | |
外币折算调整,扣除零税
|
| | | | 6 | | | | | | (152) | | |
全面亏损
|
| | | $ | (5,747) | | | | | $ | (9,818) | | |
计算中使用的普通股加权平均数: | | | | | | | | | | | | | |
− Basic and Diluted
|
| | | | 8,790,397 | | | | | | 9,569,932 | | |
每股普通股净亏损
|
| | | | | | | | | | | | |
− Basic and Diluted
|
| | | $ | (0.65) | | | | | $ | (1.01) | | |
| | |
Convertible Preferred
Shares |
| | |
Ordinary Shares
|
| |
Additional
Paid-in Capital |
| |
Accumulated
other Comprehensive loss |
| |
Accumulated
deficit |
| |
Total
Shareholders’ deficit |
| ||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2020
|
| | | | — | | | | | $ | — | | | | | | | 7,840,321 | | | | | $ | 1 | | | | | $ | 8,114 | | | | | $ | (50) | | | | | $ | (11,804) | | | | | $ | (3,739) | | |
普通股发行
|
| | | | — | | | | | | — | | | | | | | 500,000 | | | | | | — | | | | | | 500 | | | | | | — | | | | | | — | | | | | | 500 | | |
应付关联方其他应付款项转换后发行普通股
|
| | | | — | | | | | | — | | | | | | | 500,000 | | | | | | — | | | | | | 500 | | | | | | — | | | | | | — | | | | | | 500 | | |
发行A系列优先股
|
| | | | 1,833,892 | | | | | | 6,792 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
转换可转换本票后发行A系列优先股
|
| | | | 543,750 | | | | | | 2,014 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
发行B系列优先股
|
| | | | 5,443,272 | | | | | | 23,000 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
行使股票期权
|
| | | | — | | | | | | — | | | | | | | 727,676 | | | | | | — | | | | | | 86 | | | | | | — | | | | | | — | | | | | | 86 | | |
基于股份的薪酬费用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 1,363 | | | | | | — | | | | | | — | | | | | | 1,363 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (5,753) | | | | | | (5,753) | | |
外币折算调整
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | 6 | | | | | | — | | | | | | 6 | | |
Balance as of December 31, 2020
|
| | | | 7,820,914 | | | | | $ | 31,806 | | | | | | | 9,567,997 | | | | | $ | 1 | | | | | $ | 10,563 | | | | | $ | (44) | | | | | $ | (17,557) | | | | | $ | (7,037) | | |
行使股票期权
|
| | | | — | | | | | | — | | | | | | | 706,406 | | | | | | — | | | | | | 232 | | | | | | — | | | | | | — | | | | | | 232 | | |
基于股份的薪酬费用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 1,530 | | | | | | — | | | | | | — | | | | | | 1,530 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (9,666) | | | | | | (9,666) | | |
外币折算调整
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (152) | | | | | | — | | | | | | (152) | | |
Balance as of December 31, 2021
|
| | | | 7,820,914 | | | | | $ | 31,806 | | | | | | | 10,274,403 | | | | | $ | 1 | | | | | $ | 12,325 | | | | | $ | (196) | | | | | $ | (27,223) | | | | | $ | (15,093) | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
经营活动产生的现金流 | | | | | | | | | | | | | |
Net loss
|
| | | $ | (5,753) | | | | | $ | (9,666) | | |
将净亏损与经营活动中使用的现金净额进行调整: | | | | | | | | | | | | | |
Depreciation
|
| | | | 17 | | | | | | 30 | | |
基于股份的薪酬费用
|
| | | | 1,363 | | | | | | 1,530 | | |
处置财产和设备的收益
|
| | | | — | | | | | | (8) | | |
经营性资产和负债变动:
|
| | | | | | | | | | | | |
关联方其他应收账款
|
| | | | 4 | | | | | | — | | |
Prepayments
|
| | | | 192 | | | | | | (35) | | |
应付关联方的其他应付款
|
| | | | (19) | | | | | | 45 | | |
应计费用和其他负债
|
| | | | (254) | | | | | | 632 | | |
Security deposits
|
| | | | 8 | | | | | | (2) | | |
经营活动中使用的净现金
|
| | | | (4,442) | | | | | | (7,474) | | |
投资活动产生的现金流 | | | | | | | | | | | | | |
购置财产和设备
|
| | | | — | | | | | | (74) | | |
物业和设备预付款
|
| | | | (20) | | | | | | — | | |
处置财产和设备的收益
|
| | | | — | | | | | | 18 | | |
投资活动中使用的净现金
|
| | | | (20) | | | | | | (56) | | |
融资活动产生的现金流 | | | | | | | | | | | | | |
延期发行费用的支付
|
| | | | — | | | | | | (815) | | |
关联方贷款收益
|
| | | | 131 | | | | | | — | | |
偿还关联方贷款
|
| | | | (2,450) | | | | | | — | | |
发行普通股所得收益
|
| | | | 500 | | | | | | — | | |
发行可转换优先股
|
| | | | 29,792 | | | | | | — | | |
从行使股票期权开始
|
| | | | 86 | | | | | | 232 | | |
用于融资活动的现金净额
|
| | | | 28,059 | | | | | | (583) | | |
汇率对现金的影响
|
| | | | 4 | | | | | | (161) | | |
现金净(减)增
|
| | | | 23,601 | | | | | | (8,274) | | |
年初的现金
|
| | | | 2,017 | | | | | | 25,618 | | |
CASH AT END OF THE PERIOD
|
| | | $ | 25,618 | | | | | $ | 17,344 | | |
补充披露现金流量信息 | | | | | | | | | | | | | |
Interest paid
|
| | | | 19 | | | | | | — | | |
非现金投资补充披露 | | | | | | | | | | | | | |
可转换本票和应计利息转换为可转换优先股
|
| | | | 2,014 | | | | | | — | | |
将其他应付关联方款项转换为普通股
|
| | | | 500 | | | | | | — | | |
Subsidiaries
|
| |
Date of
incorporation |
| |
Place of
incorporation |
| |
Ownership
|
| |
Principal
activities |
|
Belite Bio Holdings Corp.
(“Belite Holding”) |
| | June 10, 2016 | | |
美利坚合众国
|
| | 100% owned by Belite | | | Investment holding | |
Belite Bio, LLC
(“Belite USA”) |
| | June 10, 2016 | | |
美利坚合众国
|
| |
100% owned by Belite Holding
|
| |
研发
|
|
RBP4 Pty Ltd
(“RBP4”) |
| | August 13, 2018 | | | Australia | | |
100% owned by Belite Holding
|
| | 临床试验活动 | |
Belite Bio (HK) Limited
(“Belite HK”) |
| | June 10, 2021 | | | Hong Kong | | | 100% owned by Belite | | | Investment holding | |
贝利特生物(上海)有限公司
(“Belite Shanghai”) |
| | August 12, 2021 | | | China | | | 100% owned by Belite HK | | | 临床试验活动 | |
Supplier
|
| |
2020
|
| |
2021
|
| ||||||
A | | | | $ | * | | | | | $ | 2,385 | | |
B | | | | | * | | | | | | 1,213 | | |
C | | | | | 776 | | | | | | 765 | | |
D | | | | | 1,187 | | | | | | * | | |
E | | | | | 448 | | | | | | * | | |
F | | | | | 442 | | | | | | * | | |
G | | | | | 423 | | | | | | * | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Prepayments | | | | | | | | | | | | | | | ||
其他服务的−预付款
|
| | | $ | 10 | | | | | $ | 64 | | | | ||
可抵扣增值税进项
|
| | | | 40 | | | | | | 23 | | | | ||
| | | | $ | 50 | | | | | $ | 87 | | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Laboratory equipment
|
| | | $ | 92 | | | | | $ | 141 | | | | ||
减去:累计折旧
|
| | | | (46) | | | | | | (47) | | | | ||
Total
|
| | | $ | 46 | | | | | $ | 94 | | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
研发
|
| | | $ | 488 | | | | | $ | 741 | | | | ||
Legal and consulting
|
| | | | 266 | | | | | | 525 | | | | ||
License royalties
|
| | | | 187 | | | | | | 147 | | | | ||
Other
|
| | | | 5 | | | | | | 151 | | | | ||
| | | | $ | 946 | | | | | $ | 1,564 | | | |
| | |
December 31, 2020 and 2021
|
| | | | | | | | | | | | | |||||||||||||||||||||||||||
| | |
Preferred
Shares Authorized |
| |
Preferred
Shares Issued and Outstanding |
| |
Carrying
Value |
| |
Liquidation
Value |
| |
Common
Stock Issuable Upon Conversion |
| | | | | |||||||||||||||||||||||
A系列优先股
|
| | | | 2,377,642 | | | | | $ | 2,377,642 | | | | | $ | 8,806 | | | | | $ | 8,806 | | | | | | 2,377,642 | | | | | | | ||||||||
B系列优先股
|
| | | | 5,443,272 | | | | | | 5,443,272 | | | | | | 23,000 | | | | | | 23,000 | | | | | | 5,443,272 | | | | | | | ||||||||
Total
|
| | | | 7,820,914 | | | | | | 7,820,914 | | | | | | 31,806 | | | | | | 31,806 | | | | | | 7,820,914 | | | | | | |
| | |
As of December 17,
2019 |
| |
As of December 23,
2020 |
| |
As of March 1,
2021 |
|
Risk-free interest rate
|
| |
1.72% – 1.74%
|
| |
0.51%
|
| |
0.87%
|
|
预期波动范围
|
| |
35.50% – 35.72%
|
| |
36.59%
|
| |
36.75%
|
|
Exercise multiple
|
| |
2.8
|
| |
2.8
|
| |
2.8
|
|
预期股息收益率
|
| |
—
|
| |
—
|
| |
—
|
|
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Grant Date Fair Value |
| |
Weighted
Average Remaining Term (Years) |
| |
Aggregate
Intrinsic Value |
| |||||||||||||||
Outstanding as of January 1, 2020
|
| | | | 1,335,794 | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | 9.96 | | | | | | 3,301 | | |
Granted
|
| | | | 2,807,381 | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (727,676) | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (19,601) | | | | | $ | 0.1191 | | | | | $ | 2.4733 | | | | | | — | | | | | | — | | |
Outstanding as of December 31, 2020
|
| | | | 3,395,898 | | | | | $ | 0.3832 | | | | | $ | 2.2946 | | | | | | 9.80 | | | | | | 7,834 | | |
Granted
|
| | | | 41,736 | | | | | $ | 4.2254 | | | | | $ | 0.4626 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (706,406) | | | | | $ | 0.3289 | | | | | $ | 2.3311 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (748,667) | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Outstanding Options, December 31, 2021
|
| | | | 1,982,561 | | | | | $ | 0.4626 | | | | | $ | 2.2571 | | | | | | 8.82 | | | | | $ | 4,480 | | |
截至2021年12月31日已授予并预计将授予期权
|
| | | | 844,774 | | | | | $ | 0.3935 | | | | | $ | 2.3052 | | | | | | 8.58 | | | | | $ | 1,969 | | |
截至2021年12月31日的可行使期权
|
| | | | 356,067 | | | | | $ | 0.2291 | | | | | $ | 2.4192 | | | | | | 7.99 | | | | | $ | 891 | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
研发
|
| | | $ | 77 | | | | | $ | 52 | | | | ||
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | | | ||
Total | | | | $ | 1,363 | | | | | $ | 1,530 | | | |
| | |
(In Thousands)
Years ended December 31, |
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
联邦法定税率
|
| | | | 21% | | | | | | 21% | | | | ||
State taxes
|
| | | | 8.84% | | | | | | 8.84% | | | | ||
Withholding tax
|
| | | | 0.02% | | | | | | 0.00% | | | | ||
研发信用
|
| | | | (0.03)% | | | | | | (0.33)% | | | | ||
不可扣除的费用
|
| | | | (0.27)% | | | | | | (0.20)% | | | | ||
估值免税额的变化
|
| | | | (29.54)% | | | | | | (29.31)% | | | | ||
Effective tax rate
|
| | | $ | 0.02% | | | | | $ | 0.00% | | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
递延所得税资产 | | | | | | | | | | | | | | | ||
研发学分
|
| | | $ | 59 | | | | | $ | 103 | | | | ||
净营业亏损结转
|
| | | | 3,687 | | | | | | 4,005 | | | | ||
| | | | | 3,746 | | | | | | 4,108 | | | | ||
Valuation allowance
|
| | | | (3,746) | | | | | | (4,108) | | | | ||
递延所得税净资产总额
|
| | | $ | — | | | | | $ | — | | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Numerator: | | | | | | | | | | | | | | | ||
普通股股东应占净亏损
|
| | | $ | (5,753) | | | | | $ | (9,666) | | | | ||
Denominator: | | | | | | | | | | | | | | | ||
已发行普通股加权平均数 - 基本股和稀释股
|
| | | | 8,790,397 | | | | | | 9,569,932 | | | | ||
每股净亏损 - 基本股和摊薄股
|
| | | $ | (0.65) | | | | | $ | (1.01) | | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
可转换优先股
|
| | | | 7,820,914 | | | | | | 7,820,914 | | | | ||
未偿还股票期权
|
| | | | 3,395,898 | | | | | | 1,982,561 | | | | ||
Total
|
| | | | 11,216,812 | | | | | | 9,803,475 | | | |
Name of related parties
|
| |
与公司的关系
|
|
Lin BioScience, Inc. | | | 公司的最终股东 | |
林生物科学国际有限公司 | | | 公司股东 | |
林生物科学私人有限公司 | | | 由公司最终股东控制 | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
因关联方原因 | | | | | | | | | | | | | | | ||
Lin BioScience, Inc.
|
| | | $ | 26 | | | | | $ | 71 | | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Lin BioScience, Inc.: | | | | | | | | | | | | | | | ||
研发费用
|
| | | $ | — | | | | | $ | 183 | | | | ||
专业服务费
|
| | | $ | 21 | | | | | $ | — | | | | ||
Interest Expense
|
| | | $ | 17 | | | | | $ | — | | | |
Securities/Purchaser
|
| |
Date of Issuance
|
| |
Number of Securities
|
| |
Exercise Price
|
|
Options | | | | | | | | | | |
某些董事、高级管理人员和员工 | | |
December 17, 2019
|
| |
Option to purchase up
to 1,335,794 ordinary shares |
| |
$0.1191
|
|
某些董事、高级管理人员和员工 | | |
December 23, 2020
|
| |
Option to purchase up
to 2,807,381 ordinary shares |
| |
$0.4386(1)
|
|
某些关键顾问 | | |
March 1, 2021
|
| |
Option to purchase up
to 41,736 ordinary shares |
| |
$4.2254
|
|
Securities/Purchaser
|
| |
Date of Issuance
|
| |
Number of Securities
|
| |
Exercise Price
|
|
某些董事、高级管理人员和员工 | | |
April 18, 2022#
|
| |
Option to purchase up to 1,698,667 ordinary
shares |
| |
$6.00(2)
|
|
|
Exhibit
Number |
| |
Description of Document
|
|
| 1.1† | | |
承保协议格式
|
|
| 3.1† | | |
目前有效的第二次修订和重新修订的注册人组织备忘录和章程(于2021年11月1日修订)
|
|
| 3.2† | | |
第三次修订和重新修订的注册人组织备忘录和章程(在本次发行完成后立即生效)
|
|
| 4.1† | | | 注册人美国存托凭证样本(附于附件4.3) | |
| 4.2† | | |
普通股注册人证书范本
|
|
| 4.3† | | |
根据其发行的美国存托股份的登记人、存托人、持有人和实益所有人之间的存托协议格式
|
|
| 4.4† | | |
由Belite Bio,Inc.和其中点名的Belite Bio,Inc.股东于2020年12月23日修订并重新签署的股东协议
|
|
| 4.5† | | |
由Belite Bio,Inc.和其中指名的Belite Bio,Inc.股东之间修订和重新签署的股东协议修正案日期为2021年11月1日
|
|
| 5.1† | | |
Maples and Calder(Hong Kong)LLP对正在登记的普通股的有效性和开曼群岛的某些税务问题的意见
|
|
| 8.1† | | |
Maples and Calder(Hong Kong)LLP对开曼群岛某些税务问题的意见(见附件5.1)
|
|
| 8.2† | | |
O‘Melveny&Myers LLP对某些美国税务问题的意见
|
|
| 10.1† | | |
Belite Bio,Inc.修订并重新启动股票激励计划
|
|
| 10.2† | | |
2022 Performance Incentive Plan
|
|
| 10.3† | | |
注册人与其高级管理人员之间的雇佣协议格式
|
|
| 10.4† | | |
注册人与其董事和高管之间的赔偿协议格式
|
|
| 10.5† | | |
Belite Bio,Inc.与其中指定的Belite Bio,Inc.某些投资者签订的A系列优先股购买和票据转换协议,日期为2020年1月21日
|
|
| 10.6† | | |
Belite Bio,Inc.与其中指定的Belite Bio,Inc.某些投资者之间签订的B系列优先股购买协议,日期为2020年12月23日
|
|
| 10.7#† | | |
Belite Bio,Inc.与纽约市哥伦比亚大学董事会签订的独家许可协议,日期为2016年9月13日
|
|
| 10.8† | | |
Belite Bio,Inc.与纽约市哥伦比亚大学受托人之间的独家许可协议修正案,日期为2017年8月15日
|
|
| 10.9† | | |
纽约市哥伦比亚大学董事会于2018年5月3日签发的同意书
|
|
| 10.10#† | | |
2019年3月27日Belite Bio,Inc.与纽约市哥伦比亚大学受托人签署的独家许可协议第二修正案
|
|
| 10.11#† | | |
2019年10月24日Belite Bio,Inc.与纽约市哥伦比亚大学受托人签署的独家许可协议第三修正案
|
|
| 10.12#† | | |
2021年9月1日,Belite Bio,Inc.与纽约市哥伦比亚大学受托人之间达成的独家许可协议第四修正案
|
|
| 10.13#† | | |
2022年2月4日由Belite Bio,Inc.与纽约市哥伦比亚大学受托人签署的《独家许可协议第五修正案》
|
|
| 10.14† | | |
Belite Bio,Inc.和Lin BioScience,Inc.签订的LBS-008研发服务协议,日期为2021年7月1日
|
|
|
Exhibit
Number |
| |
Description of Document
|
|
| 10.15† | | |
Belite Bio,Inc.和Lin BioScience,Inc.于2022年2月23日签署的LBS-008研发服务协议第一修正案
|
|
| 21.1† | | |
注册人重要子公司名单
|
|
| 23.1 | | |
Consent of Friedman LLP
|
|
| 23.2† | | | Maples and Calder(Hong Kong)LLP同意(见附件5.1) | |
| 23.3† | | |
商务金融律师事务所同意
|
|
| 24.1† | | |
授权书(包括在签名页上)
|
|
| 99.1† | | |
《商业行为和道德准则》(紧接本次发售完成前生效)
|
|
| 99.2† | | |
商务金融律师事务所对某些中国法律问题的意见
|
|
| 99.3† | | |
Consent of John M. Longo
|
|
| 99.4† | | |
Consent of Ita Lu
|
|
| 99.5† | | |
Consent of Gary C. Biddle
|
|
| 107† | | |
Filing Fee Table
|
|
| | | | BELITE BIO, INC | | |||
| | | | By: | | |
/s/ Yu-Hsin Lin
Name: Yu-Hsin Lin
职务: 首席执行官兼董事长 |
|
|
Signature
|
| |
Title
|
|
|
/s/ Yu-Hsin Lin
Name: Yu-Hsin Lin
|
| | 首席执行官、董事会主席(首席执行官) | |
|
/s/ Wan-Shan Chen
Name: Wan-Shan Chen
|
| | Director | |
|
/s/ Hung-Wei Chen
Name: Hung-Wei Chen
|
| | Director | |
|
/s/ Hao-Yuan Chuang
Name: Hao-Yuan Chuang
|
| | 董事首席财务官(首席财务会计官) | |
| | | | 授权的美国代表 | | |||
| | | | By: | | |
/s/ Donald J. Puglisi
Name: Donald J. Puglisi
标题:管理董事 |
|